Advanced Cell Technology Comments on the Results of the Midterm Elections.

ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB:ACTC) Chairman and CEO William Caldwell today commented on the midterm United States Congressional elections held Tuesday, November 7, 2006. "Embryonic stem cells hold the potential to provide a well-characterized and reproducible source of replacement cells for clinical studies and the treatment of devastating diseases and injuries such as heart disease, cancer, macular degeneration, Parkinson's disease, Alzheimer's disease, and diabetes. We have been encouraged by our progress to date, though there is little doubt that in the United States progress in our field has been hampered by the ban on federal funding of research on new embryonic stem cell lines. I believe the changing political tide brings us yet another step closer to federal funding for embryonic stem cell research and ultimately to developing therapies for devastating and life threatening indications."

Advanced Cell Technology strongly supported both H.R. 810 and S. 2754, which were legislative efforts put before Congress in July 2006 to support the use of federal funds to research frozen hESC lines and to promote medical research and development of alternative hESC lines through techniques that do not harm a human embryo or fetus.

"While we were disappointed that H.R. 810 and S. 2754 were not enacted into law, we have been encouraged by the bipartisan support of recent legislative efforts to provide federal funding for embryonic stem cell research," Mr. Caldwell continued. "We are also encouraged by the widespread support of embryonic stem cell research by the American public as evidenced by the results of the recent Congressional elections. It may be only a matter of time before the federal government provides the expanded funding that scientists in laboratories in universities at pharmaceutical and biotechnology companies across the country require to move novel therapies from the lab to the clinic and, ultimately, to the bedside. Eventually, this funding could accelerate the programs for companies researching both embryonic and adult stem cell therapies including but not limited to Advanced Cell Technology, Geron Corporation, StemCells Inc., and Aastrom Biosciences. We will continue to work with our technological, ethical, and legislative partners to focus on driving therapies to the clinic."

Advanced Cell Technology's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina. Advanced Cell Technology also continues to investigate the use of human embryonic stem cell-derived hemangioblasts for vascular restoration of organs and limbs.

About Advanced Cell Technology, Inc.

Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, please visit: www.advancedcell.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To read or download Advanced Cell's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.